1	Leisure time sedentary behaviour and risks of breast, colorectal, and
2	prostate cancer: A Mendelian randomization analysis
3	Nikos Papadimitriou ¹ , Nabila Kazmi ² , Niki Dimou ¹ , Konstantinos K Tsilidis ^{3,4} , Richard M
4	Martin ^{2,5,6} , Sarah J Lewis ⁵ , Brigid M Lynch ⁷⁻⁹ , Michael Hoffmeister ¹⁰ , Sun-Seog Kweon ^{11,12} ,
5	Li Li ¹³ , Roger L Milne ^{7,8,14} , Lori C Sakoda ^{15,16} , Robert E Schoen ¹⁷ , Amanda I Phipps ^{16,18} ,
6	Jane C Figueiredo ^{19,20} , Ulrike Peters ^{16,18} , Suzanne C. Dixon-Suen ^{7,21} , Marc J Gunter ^{1,4} , Neil
7	Murphy ¹
8	
9	¹ . Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon,
10	France.
11	² . MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical
12	School, University of Bristol, Bristol, UK.
13	³ . Department of Hygiene and Epidemiology, University of Ioannina School of Medicine,
14	Ioannina, Greece.
15	⁴ . Department of Epidemiology and Biostatistics, School of Public Health, Imperial College
16	London, London, UK.
17	⁵ . Bristol Medical School, Department of Population Health Sciences, University of Bristol,
18	Bristol, UK.
19	⁶ . National Institute for Health Research (NIHR) Bristol Biomedical Research Centre,
20	University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol,
21	Bristol, UK.
22	⁷ . Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
23	⁸ . Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global
24	Health, The University of Melbourne, Melbourne, Victoria, Australia.

- ⁹. Physical Activity Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria,
- 26 Australia.
- ¹⁰ Division of Clinical Epidemiology and Aging Research, German Cancer Research Center
- 28 (DKFZ), Heidelberg, Germany.
- 29 ¹¹ Department of Preventive Medicine, Chonnam National University Medical School,
- 30 Gwangju, Korea.
- 31 ¹² Jeonnam Regional Cancer Center, Chonnam National University Hwasun Hospital,
- 32 Hwasun, Korea.
- ¹³ Department of Family Medicine, University of Virginia, Charlottesville, Virginia, USA.
- ¹⁴ Precision Medicine, School of Clinical Sciences at Monash Health, Monash University,
- 35 Clayton, Victoria, Australia.
- ¹⁵ Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
- ¹⁶ Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington,
- 38 USA.
- ¹⁷ Department of Medicine and Epidemiology, University of Pittsburgh Medical Center,
- 40 Pittsburgh, Pennsylvania, USA.
- 41 ¹⁸.Department of Epidemiology, University of Washington, Seattle, Washington, USA.
- 42 ¹⁹ Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
- 43 Medical Center, Los Angeles, CA, USA.
- ²⁰ Department of Preventive Medicine, Keck School of Medicine, University of Southern
- 45 California, Los Angeles, CA, USA.
- 46 ²¹ Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences,
- 47 Deakin University, Geelong, Victoria, Australia.

- 48 Corresponding author: Dr Nikos Papadimitriou, Branch of Nutrition and Metabolism,
- 49 International Agency for Research on Cancer, 150 Cours Albert Thomas, 69008 Lyon,
- 50 France, Tel.: +33 4 72738485, E-mail: papadimitrioun@iarc.who.int
- 51
- 52 Keywords: Mendelian randomization, Sedentary activities, Breast cancer, Colorectal cancer,
- 53 Prostate cancer
- 54
- 55 Article category
- 56 Cancer Epidemiology
- 57
- 58 Abbreviations
- 59
- 60 BMI: body mass index
- 61 IVW: inverse-variance weighted
- 62 GWAS: genome-wide association study
- 63 LD: linkage disequilibrium
- 64 MR: Mendelian randomization
- 65 PSA: prostate-specific antigen
- 66 OR: odds ratio
- 67 RCT: randomised control trial
- 68 SNP: single nucleotide polymorphism
- 69 SD: Standard deviation

70

71

73 Novelty and impact

- 74
- 75 Evidence from observational studies that examined associations between sedentary
- 76 behaviours and common cancers is mixed and causality is uncertain. In our Mendelian
- randomization analyses, higher levels of leisure television watching were found to increase
- 78 the risks of breast and colorectal cancer, suggesting that the that the promotion of lowering
- respective strategy in the primary prevention of these
- 80 commonly diagnosed cancers.

81 Abstract (250 words)

82

83	Sedentary behaviours have been associated with increased risks of some common cancers in
84	epidemiological studies; however, it is unclear if these associations are causal. We examined
85	potential causal associations between self-reported leisure television watching and computer
86	use and risks of breast, colorectal, and prostate cancer using a two-sample Mendelian
87	randomization framework. Genetic variants were identified from a recent genome-wide
88	association study (GWAS). Cancer data were obtained from cancer GWAS consortia.
89	Additional sensitivity analyses were applied to examine the robustness of the results.
90	A 1-standard deviation increment in hours of television watching increased risk of breast
91	(OR: 1.15, 95% confidence interval [CI]: 1.05,1.26) and colorectal cancer (OR: 1.32, 95%CI:
92	1.16,1.49) with little evidence of an association for prostate cancer risk. In multivariable
93	models adjusted for years of education, the effect estimates for television watching were
94	attenuated (breast cancer, OR: 1.08, 95%CI: 0.92, 1.27; colorectal cancer, OR: 1.08, 95%CI:
95	0.90,1.31). Post-hoc analyses showed that years of education might have a possible
96	confounding and mediating role in the association between television watching with breast
97	and colorectal cancer. Consistent results were observed by sex (colorectal cancer), anatomical
98	subsites, and cancer subtypes. There was little evidence of associations between computer use
99	and cancer risk.
100	We found evidence of positive associations between hours of television watching and risks of
101	breast and colorectal cancer. However, these findings should be interpreted cautiously given
102	the complex role of education. Future studies using objective measures of exposure can
103	provide new insights into the possible role of sedentary behaviour in cancer development.
104	

105 Introduction

106	Breast, colorectal, and prostate cancer are three of the most common malignancies
107	collectively accounting for an estimated 29% of new cancer cases in 2020 (1). Sedentary
108	behaviour is defined as any waking behaviour characterized by energy expenditure ≤ 1.5
109	metabolic equivalents while in a sitting, reclining, or lying posture (2). The most common
110	sedentary activities are television watching and computer use; these are more accurately
111	recalled than total sedentary time and are therefore commonly used as surrogates of sedentary
112	behaviour (3). A recent US study reported that approximately two-thirds of adults spent two
113	or more hours each day watching television and around 50% spend more than one hour using
114	their computer outside work (4). Studies in the UK and in the US estimated that adults on
115	average spend five to six hours per day sitting (4, 5). Given such a high prevalence, sedentary
116	behaviours represent an important public health challenge as they have been linked with
117	multiple adverse health outcomes (6, 7).
118	Numerous observational studies have examined the associations between sedentary
118 119	Numerous observational studies have examined the associations between sedentary behaviours and the risks of breast, colorectal, and prostate cancer (8). A meta-analysis of
119	behaviours and the risks of breast, colorectal, and prostate cancer (8). A meta-analysis of
119 120	behaviours and the risks of breast, colorectal, and prostate cancer (8). A meta-analysis of case-control and cohort studies reported that sedentary behaviour was not associated with
119 120 121	behaviours and the risks of breast, colorectal, and prostate cancer (8). A meta-analysis of case-control and cohort studies reported that sedentary behaviour was not associated with colorectal cancer risk (8). More recently, however, a UK Biobank analysis, found that greater
119 120 121 122	behaviours and the risks of breast, colorectal, and prostate cancer (8). A meta-analysis of case-control and cohort studies reported that sedentary behaviour was not associated with colorectal cancer risk (8). More recently, however, a UK Biobank analysis, found that greater volumes of television watching was associated with elevated colon cancer risk (9). The
 119 120 121 122 123 	behaviours and the risks of breast, colorectal, and prostate cancer (8). A meta-analysis of case-control and cohort studies reported that sedentary behaviour was not associated with colorectal cancer risk (8). More recently, however, a UK Biobank analysis, found that greater volumes of television watching was associated with elevated colon cancer risk (9). The aforementioned meta-analysis did not observe any significant associations between sedentary
 119 120 121 122 123 124 	behaviours and the risks of breast, colorectal, and prostate cancer (8). A meta-analysis of case-control and cohort studies reported that sedentary behaviour was not associated with colorectal cancer risk (8). More recently, however, a UK Biobank analysis, found that greater volumes of television watching was associated with elevated colon cancer risk (9). The aforementioned meta-analysis did not observe any significant associations between sedentary behaviour and risk of prostate cancer (8). For breast cancer, when the meta-analysis included
 119 120 121 122 123 124 125 	behaviours and the risks of breast, colorectal, and prostate cancer (8). A meta-analysis of case-control and cohort studies reported that sedentary behaviour was not associated with colorectal cancer risk (8). More recently, however, a UK Biobank analysis, found that greater volumes of television watching was associated with elevated colon cancer risk (9). The aforementioned meta-analysis did not observe any significant associations between sedentary behaviour and risk of prostate cancer (8). For breast cancer, when the meta-analysis included cohort studies only, sedentary behaviour was associated with a higher breast cancer risk (8).
 119 120 121 122 123 124 125 126 	behaviours and the risks of breast, colorectal, and prostate cancer (8). A meta-analysis of case-control and cohort studies reported that sedentary behaviour was not associated with colorectal cancer risk (8). More recently, however, a UK Biobank analysis, found that greater volumes of television watching was associated with elevated colon cancer risk (9). The aforementioned meta-analysis did not observe any significant associations between sedentary behaviour and risk of prostate cancer (8). For breast cancer, when the meta-analysis included cohort studies only, sedentary behaviour was associated with a higher breast cancer risk (8). Clarifying causal associations from such observational evidence is hampered by inherent

130 exposures of interest to make causal inferences between an exposure and an outcome (13). 131 Unlike traditional observational epidemiology, MR can be largely free of conventional 132 confounding owing to the random independent assignment of alleles during meiosis (14). In 133 addition, multivariable MR methods have been developed to adjust for confounding if found 134 to be present. There should be no reverse causation in MR studies, as germline genetic 135 variants are fixed at conception and are consequently unaffected by the disease process (14). 136 A recent MR analysis reported a positive effect estimate for television watching with lung 137 cancer risk (15). However, similar analyses investigating possible causal effects of sedentary 138 behaviours for other common cancers have not been conducted. 139 We used a two-sample MR framework to examine potential causal associations 140 between self-reported sedentary behaviours and risks of breast, colorectal, and prostate 141 cancer. Genetic variants associated with leisure television watching and computer use were 142 identified from a recent genome-wide association study (GWAS) (16) and we then examined 143 how these genetic variants related to risks of breast, colorectal, and prostate cancer using 144 large-scale GWAS consortia data (17-19). 145 146 **Materials and Methods** 147 Data on leisure sedentary behaviours 148 Summary-level data on duration of leisure sedentary behaviours were obtained from a 149

150 UK Biobank using BOLT-LMM v2.3beta2, using a mixed linear model correcting for

151 population structure and cryptic relatedness (16). To ascertain the duration of the sedentary

recently published GWAS conducted in 408,815 participants of European ancestry from the

- 152 behaviours, participants within the UK Biobank were asked three questions, "In a typical
- 153 DAY, how many hours do you spend watching television?", "In a typical DAY, how many
- 154 hours do you spend using the computer? (Do not include using a computer at work)" and "In

155	a typical DAY, how many hours do you spend driving?"(16). This GWAS identified 209 and
156	52 genome-wide-significant single nucleotide polymorphisms (SNPs) (P-value $< 5 \times 10^{-8}$) for
157	leisure television watching and computer use respectively using a linkage disequilibrium (LD)
158	of $R^2 < 0.005$ within a five megabase window (Supplemental Tables 1-2). The GWAS also
159	identified five genetic variants associated with driving; however, we did not include these
160	instruments in our MR analyses due to low statistical power (see Statistical power, below).
161	The 261 SNPs included in both instruments were identified in 204 loci demonstrating a partial
162	overlap between the two phenotypes with 22 common loci. The selected SNPs explained
163	approximately 2% and 0.5% of the variability in television watching and computer use
164	respectively.
165	
166	Data on breast, colorectal, and prostate cancer
167	Summary data for the associations of the above genetic variants with breast cancer
167 168	Summary data for the associations of the above genetic variants with breast cancer were obtained from a GWAS of 247,173 women (133,384 breast cancer cases and 113,789
168	were obtained from a GWAS of 247,173 women (133,384 breast cancer cases and 113,789
168 169	were obtained from a GWAS of 247,173 women (133,384 breast cancer cases and 113,789 controls) of European ancestry from the Breast Cancer Association Consortium (19). We
168 169 170	were obtained from a GWAS of 247,173 women (133,384 breast cancer cases and 113,789 controls) of European ancestry from the Breast Cancer Association Consortium (19). We included six related outcomes in our analyses (overall, luminal A, luminal B, luminal B HER2
168 169 170 171	were obtained from a GWAS of 247,173 women (133,384 breast cancer cases and 113,789 controls) of European ancestry from the Breast Cancer Association Consortium (19). We included six related outcomes in our analyses (overall, luminal A, luminal B, luminal B HER2 negative, HER2 enriched, and triple negative breast cancer).
168 169 170 171 172	were obtained from a GWAS of 247,173 women (133,384 breast cancer cases and 113,789 controls) of European ancestry from the Breast Cancer Association Consortium (19). We included six related outcomes in our analyses (overall, luminal A, luminal B, luminal B HER2 negative, HER2 enriched, and triple negative breast cancer). For colorectal cancer, summary data from 98,715 participants (52,775 colorectal
168 169 170 171 172 173	 were obtained from a GWAS of 247,173 women (133,384 breast cancer cases and 113,789 controls) of European ancestry from the Breast Cancer Association Consortium (19). We included six related outcomes in our analyses (overall, luminal A, luminal B, luminal B HER2 negative, HER2 enriched, and triple negative breast cancer). For colorectal cancer, summary data from 98,715 participants (52,775 colorectal cancer cases and 45,940 controls) were drawn from a meta-analysis within the ColoRectal
168 169 170 171 172 173 174	 were obtained from a GWAS of 247,173 women (133,384 breast cancer cases and 113,789 controls) of European ancestry from the Breast Cancer Association Consortium (19). We included six related outcomes in our analyses (overall, luminal A, luminal B, luminal B HER2 negative, HER2 enriched, and triple negative breast cancer). For colorectal cancer, summary data from 98,715 participants (52,775 colorectal cancer cases and 45,940 controls) were drawn from a meta-analysis within the ColoRectal Transdisciplinary Study, the Colon Cancer Family Registry, and the Genetics and
168 169 170 171 172 173 174 175	 were obtained from a GWAS of 247,173 women (133,384 breast cancer cases and 113,789 controls) of European ancestry from the Breast Cancer Association Consortium (19). We included six related outcomes in our analyses (overall, luminal A, luminal B, luminal B HER2 negative, HER2 enriched, and triple negative breast cancer). For colorectal cancer, summary data from 98,715 participants (52,775 colorectal cancer cases and 45,940 controls) were drawn from a meta-analysis within the ColoRectal Transdisciplinary Study, the Colon Cancer Family Registry, and the Genetics and Epidemiology of Colorectal Cancer consortia (17). We included five outcomes in our

179	For prostate cancer, summary data from a meta-analysis of 140,254 (79,148 prostate
180	cancer cases and 61,106 controls) men of European ancestry in the Prostate Cancer
181	Association Group to Investigate Cancer-Associated Alterations in the Genome and the
182	Genetic Associations and Mechanisms in Oncology/Elucidating Loci Involved in Prostate
183	Cancer Susceptibility consortia (18). The same consortia also conducted a GWAS of
184	aggressive prostate cancer involving 15,167 cases and 58,308 controls, in which cancer cases
185	were defined as aggressive based on the following characteristics: Gleason score ≥ 8 , Prostate-
186	Specific Antigen (PSA)>100 ng/mL, metastatic disease (M1) or death from prostate cancer
187	(18).
188	All cancer estimates for the two exposures of interest are provided in Supplemental
189	Tables 3-8. All participants provided written informed consent. Ethics were approved by
190	respective institutional review boards.
191	
192	Statistical power
193	The statistical power was calculated a priori using an online tool at
194	http://cnsgenomics.com/shiny/mRnd/ (20). Under the scenario of a type 1 error of 5%, for
195	leisure television use an expected OR per 1 standard deviation (SD) ≥ 1.09 , ≥ 1.14 and ≥ 1.11
196	was needed to have adequate statistical power (> 80%) for overall breast, colorectal and
197	prostate cancer respectively. Supplemental Table 9 presents the power estimates for the three
198	exposures of interest by subtypes or subsites of breast, colorectal, and prostate cancer.
199	
200	Statistical analysis
201	A two-sample MR approach using summary data and the fixed-effect IVW method
201 202	A two-sample MR approach using summary data and the fixed-effect IVW method was implemented. All results correspond to an OR per 1-SD increment in genetically-

204	use: 1.2 hours/day).	The heterogeneity	of the causal e	estimates by	cancer subtype	(breast
-----	----------------------	-------------------	-----------------	--------------	----------------	---------

- 205 cancer), subsite (colorectal cancer) and sex (colorectal cancer only) was investigated by
- 206 calculating the I^2 metric using a fixed effect meta-analysis model (21).
- 207

208 Sensitivity analyses

209 MR studies have three main assumptions that must be satisfied in order for their causal 210 estimates to be valid, which in the context of this study are: 1) the genetic instrument is 211 strongly associated with the levels of exposure (sedentary behaviour); 2) the genetic 212 instrument is not associated with any potential confounder of the exposure (sedentary 213 behaviour)—outcome (cancer) association; and 3) the genetic instrument does not affect the 214 outcome (cancer) independently of the exposure (sedentary behaviour) (i.e. exclusion of 215 horizontal pleiotropy). The strength of each genetic instrument can be evaluated through the 216 F-statistic (provided by the initial GWAS) (16). Several sensitivity analyses were conducted 217 to identify and correct for the presence of horizontal pleiotropy in the results from the main 218 analysis. Cochran's Q was computed to quantify heterogeneity across the individual causal 219 effects, with a P-value ≤ 0.05 indicating the presence of pleiotropy, and consequently, a 220 random effects IVW MR analysis was used (21, 22). MR-Egger regression was performed in 221 which the intercept term can deviate from zero allowing estimation of the causal effect even 222 in the presence of invalid genetic variants. Large deviations from zero represent the presence 223 of horizontal pleiotropic effects across the genetic variants. In such a case, the slope of the 224 MR-Egger regression provides valid MR estimates when the pleiotropic effects of the genetic 225 variants are independent from the genetic associations with the exposure (23, 24). Moreover, 226 causal estimates were also computed using the weighted-median method that can give valid 227 MR estimates under the presence of horizontal pleiotropy when up to 50% of the included 228 instruments are invalid (25). The MR pleiotropy residual sum and outlier test (MR-PRESSO)

229 was also used to assess the presence of pleiotropy. The MR-PRESSO test relies on a 230 regression framework to identify outlying genetic variants which may potentially be 231 pleiotropic, we then reran the analysis after excluding these outlying variants (26). We also examined the selected genetic instruments and their proxies $(r^2 > 0.8)$ and their associations 232 233 with secondary phenotypes (P-value $< 5 \times 10-8$) in populations of European descent in 234 Phenoscanner (http://www.phenoscanner.medschl.cam.ac.uk/) to explore potential pleiotropy 235 of the included SNPs. Since several of the genetic variants were also associated with adiposity 236 or education-related phenotypes - such as body mass index (BMI) and educational attainment 237 - we performed multivariable MR to investigate whether any initial significant associations 238 for sedentary behaviour are confounded by these two traits as well as additional secondary 239 traits such as lifetime smoking and alcohol consumption which have previously been linked 240 with cancer risk (27-29). For BMI, summary data from a GWAS meta-analysis of about 241 700,000 participants of European descent within the Genetic Investigation of ANthropometric 242 Traits (GIANT) consortium and UK Biobank was obtained (30). For years of educational 243 attainment, we obtained summary level data from a published GWAS of 1.1 million 244 participants of European descent within the Social Science Genetic Association Consortium 245 and which measured the number of completed years of schooling among those individuals 246 (31). Data on alcohol consumption (drinks per week) was drawn from a GWAS of 1.2 million 247 individuals (32). The data for lifetime smoking was obtained from a recent GWAS and MR 248 study on causal effects of lifetime smoking on risk for depression and schizophrenia (33). In 249 the current analysis we used data of 766,345 participants which is publicly available. All 250 relevant summary statistics for the multivariable MR analyses is given in supplemental tables 251 10-17. For multivariable MR, we also calculated two variables: the conditional 252 $F_{early life body size}$, $F_{adult body size}$ which can be used to examine how much variance the 253 genetic variants explain on the main (sedentary behaviours) and secondary exposures (e.g.,

254	years of education); F values over 10 suggest little evidence of weak instrument bias (34).
255	Finally, as a post-hoc analysis based on the results from the multivariable MR and trying to
256	understand the observed attenuation, we also conducted a bidirectional MR study to examine
257	the associations between sedentary behaviours and the four secondary traits (BMI, years of
258	education, alcohol consumption, and lifetime smoking) (supplemental tables 18-21).
259	All the analyses were conducted using the MendelianRandomization and
260	TwoSampleMR packages, while the LD clumping (LD < 0.001) in the multivariable MR
261	analyses between SNPs of sedentary behaviour phenotypes with those for the secondary traits
262	was done using the ieugwasr R package (https://mrcieu.github.io/ieugwasr/) and the R
263	programming language (version 4.1.2) (35-37). Reporting guidelines for MR studies were
264	followed (38, 39).
265	
266	Results
266 267	Results MR estimates for leisure television watching
267	MR estimates for leisure television watching
267 268	MR estimates for leisure television watching A 1 SD (1.5 hours/day) increment in genetically-predicted duration of leisure
267 268 269	MR estimates for leisure television watching A 1 SD (1.5 hours/day) increment in genetically-predicted duration of leisure television watching increased breast cancer risk (OR per 1 SD: 1.15, 95% confidence interval
267 268 269 270	MR estimates for leisure television watching A 1 SD (1.5 hours/day) increment in genetically-predicted duration of leisure television watching increased breast cancer risk (OR per 1 SD: 1.15, 95% confidence interval [CI]: 1.05, 1.26, P-value: 0.002) (Table 1). Similar magnitude positive effect estimates were
267 268 269 270 271	MR estimates for leisure television watching A 1 SD (1.5 hours/day) increment in genetically-predicted duration of leisure television watching increased breast cancer risk (OR per 1 SD: 1.15, 95% confidence interval [CI]: 1.05, 1.26, P-value: 0.002) (Table 1). Similar magnitude positive effect estimates were found for all molecular subtypes of breast cancer (I ² = 0%, P-heterogeneity=0.98) (Table 1).
267 268 269 270 271 272	MR estimates for leisure television watching A 1 SD (1.5 hours/day) increment in genetically-predicted duration of leisure television watching increased breast cancer risk (OR per 1 SD: 1.15, 95% confidence interval [CI]: 1.05, 1.26, P-value: 0.002) (Table 1). Similar magnitude positive effect estimates were found for all molecular subtypes of breast cancer (I ² = 0%, P-heterogeneity=0.98) (Table 1). A 1 SD increment in genetically-predicted duration of leisure television watching
267 268 269 270 271 272 273	MR estimates for leisure television watching A 1 SD (1.5 hours/day) increment in genetically-predicted duration of leisure television watching increased breast cancer risk (OR per 1 SD: 1.15, 95% confidence interval [CI]: 1.05, 1.26, P-value: 0.002) (Table 1). Similar magnitude positive effect estimates were found for all molecular subtypes of breast cancer (I ² = 0%, P-heterogeneity=0.98) (Table 1). A 1 SD increment in genetically-predicted duration of leisure television watching increased colorectal cancer risk (OR per 1 SD: 1.32, 95% CI: 1.16, 1.49, P-value: 2×10 ⁻⁵)
267 268 269 270 271 272 273 273	MR estimates for leisure television watchingA 1 SD (1.5 hours/day) increment in genetically-predicted duration of leisuretelevision watching increased breast cancer risk (OR per 1 SD: 1.15, 95% confidence interval[CI]: 1.05, 1.26, P-value: 0.002) (Table 1). Similar magnitude positive effect estimates werefound for all molecular subtypes of breast cancer ($I^2 = 0\%$, P-heterogeneity=0.98) (Table 1).A 1 SD increment in genetically-predicted duration of leisure television watchingincreased colorectal cancer risk (OR per 1 SD: 1.32, 95% CI: 1.16, 1.49, P-value: 2×10^{-5})with similar significant estimates being observed for men and women ($I^2 = 42\%$, P-
267 268 269 270 271 272 273 274 275	MR estimates for leisure television watching A 1 SD (1.5 hours/day) increment in genetically-predicted duration of leisure television watching increased breast cancer risk (OR per 1 SD: 1.15, 95% confidence interval [CI]: 1.05, 1.26, P-value: 0.002) (Table 1). Similar magnitude positive effect estimates were found for all molecular subtypes of breast cancer ($I^2 = 0$ %, P-heterogeneity=0.98) (Table 1). A 1 SD increment in genetically-predicted duration of leisure television watching increased colorectal cancer risk (OR per 1 SD: 1.32, 95% CI: 1.16, 1.49, P-value: 2×10 ⁻⁵) with similar significant estimates being observed for men and women ($I^2 = 42$ %, P- heterogeneity=0.19) and by subsite ($I^2 = 45$ %, P-heterogeneity=0.17) (Table 2).

278	0.84, 1.06, P-value:0.34) or aggressive (OR per 1 SD: 0.95, 95% CI: 0.81, 1.13, P-value:0.59)
279	(overall vs aggressive; $I^2 = 0\%$, P-heterogeneity=0.92) prostate cancer (Table 3).
280	Based on the Cochran's Q values there was evidence of heterogeneity of SNP effects
281	for most outcomes except for triple negative breast cancer (Tables 1-3). Scatter plots (with
282	coloured lines representing the slopes of the different regression analyses) and funnel plots of
283	the association between leisure television watching and the risk of breast, colorectal and
284	prostate cancer risk are presented in Supplemental Figures 1-6.
285	The multivariable MR analysis adjusting for years of education led to the attenuation
286	of all effect estimates between genetically-predicted television watching and the risk of breast
287	(OR per 1 SD: 1.08, 95% CI: 0.92, 1.27) and colorectal cancer (OR per 1 SD: 1.08, 95% CI:
288	0.90, 1.31) (Figure 1, Supplemental Table 22). Additional attenuations were observed for the
289	models adjusting for lifetime smoking. For women, risk estimates for colorectal cancer were
290	attenuated towards the null in all multivariable MR models adjusting for each of the four
291	secondary traits (Figure 1, Supplemental Table 22). Finally, genetically-predicted television
292	watching was associated with HER2 negative, HER2 positive, and triple negative breast
293	cancer after adjusting for BMI in the multivariable MR models with effect sizes ranging from
294	1.32 to 1.46 per SD (Figure 1).

295

296 MR estimates for leisure computer use

There was little evidence of any causal effect of longer duration of genetically predicted leisure computer use with overall breast, colorectal, and prostate cancer (Tables 1-3). Inverse effect-estimates were found for triple negative breast cancer (OR per 1 SD: 0.68, 95% CI: 0.50, 0.93, P-value: 0.02) and rectal cancer (OR per 1 SD: 0.66, 95% CI: 0.49, 0.89, P-value: 6×10^{-3}) (Tables 1,2). Despite this, little evidence of heterogeneity was found by breast cancer subtype ($I^2 = 36\%$, P-heterogeneity=0.17), colorectal cancer subsite ($I^2 = 45\%$,

303	P-heterogeneity=0.15	, or by prostate ca	ncer status (overall	vs aggressive; I'	$^{2} = 0\%, P$ -

heterogeneity=0.34), or sex (colorectal cancer: $I^2 = 31\%$, P-heterogeneity=0.23).

305 Based on Cochran's Q values, heterogeneity in SNP effects was found for overall

306 breast cancer, luminal A breast cancer, luminal B breast cancer, and colorectal cancer. Scatter

307 plots (with coloured lines representing the slopes of the different regression analyses) and

308 funnel plots of the association between leisure computer use and risks of breast, colorectal

and prostate cancer are presented in Supplemental Figures 7-12.

310 In the multivariable MR analysis for triple negative breast cancer, after adjusting for

311 years of education, alcohol, or BMI the inverse effect estimates for genetically-predicted

312 computer use found in the univariable MR analysis were no longer statistically significant

313 with the new attenuated effect sizes ranging from 0.73 to 1.06 per SD (Figure 1, Supplemental

Table 22). Similarly, the inverse effect estimates for rectal cancer observed in the univariable

analysis were attenuated after adjusting for years of education or alcohol consumption (Figure

316 1, Supplemental Table 22).

317

318 Evaluation of assumptions and sensitivity analyses

319 The strength of the genetic instruments according to the F-statistic was ≥ 10 for both 320 exposures of interest and ranged between 23 and 164 (Supplemental Tables 1-3). Little 321 evidence of directional pleiotropy was observed based on the MR-Egger's test (MR-Egger 322 intercept P-values > 0.05) (Tables 1-3). The effect estimates from MR Egger regression 323 models were generally in the same direction with those from the main analysis but with wider 324 confidence intervals (Tables 1-3). Similarly, the weighted-median approach effect estimates 325 were consistent in direction and magnitude to the IVW models (Tables 1-3). The MR-326 PRESSO analysis identified several (10 in total) outlying SNPs (Supplemental Table 23); 327 however, no major differences were observed when these outlying genetic variants were

328	excluded from the analyses (Tables 1-3). After examining Phenoscanner, we found that
329	several of the genetic variants were also associated with adiposity or education-related
330	phenotypes, such as BMI and highest qualification (Supplemental Table 24). In the
331	multivariable MR framework, the conditional F statistics were in general above 10 (indicating
332	little evidence of weak instrument bias) for both our exposures of interest and the adjusting
333	factors with a few exceptions. For models including television watching and years of
334	education, conditional F statistics for both variables were below 10. Also, adjusting for BMI
335	or years of education resulted in low F statistics (<10) for computer use.
336	
337	MR estimates for the bidirectional MR
338	In post-hoc analyses, inverse bidirectional associations were observed between the
339	genetically-predicted duration of leisure television watching and years of education. A one
340	SD increase in genetically-predicted duration of leisure television watching reduced years of
341	education by 0.54 SD (95% CI: -0.58 to -0.49). Similarly, a one SD increase in genetically-
342	predicted years of education reduced duration of leisure television watching by 0.63 SD (95%
343	CI: -0.66 to -0.59) (Figure 2, Supplemental Tables 25,26). These observations taken together
344	with the inverse effect estimate found for years of years of education with breast and
345	colorectal cancer (Supplemental Table 27) point to education having a complex dual
346	confounding and mediating role in the association between television watching with breast
347	and colorectal cancer risk. Contrary to this, positive bidirectional associations were observed
348	for genetically-predicted duration of leisure computer use ($beta_{computer use \rightarrow education} 0.59$;
349	95% CI: 0.48 to 0.70 and $beta_{education \rightarrow computer use}$ 0.34; 95% CI: 0.30 to 0.37).
350	Additionally, positive bidirectional associations were observed between the genetically-
351	predicted duration of leisure television watching with BMI and smoking status while, inverse
352	bidirectional associations were observed between the genetically-predicted duration of leisure

353	computer use and smoking status. Finally, alcohol consumption was inversely associated with
354	computer use (Figure 2, Supplemental Tables 25,26).

- 355
- 356 Discussion

357 In this MR analysis, a high level of genetically-predicted television watching 358 increased risks of breast and colorectal cancer. The effect estimates for television watching 359 were robust according to most of the univariable sensitivity analyses conducted to assess the 360 influence of pleiotropy. After multivariable MR adjustment for years of education, the 361 positive effects were attenuated; however, our post-hoc analyses suggest that education has a 362 complex dual confounding and mediating role in the association between television watching 363 with these cancers and adjustment for years of education is not appropriate. We found little evidence that genetically-predicted leisure computer use was associated with breast, 364 365 colorectal, and prostate cancer. 366 Inconsistent results have been reported in prospective cohort studies that have 367 examined the association between sedentary behaviours and breast cancer risk. A recent meta-368 analysis reported a statistically significant 10% higher risk for the highest sedentary behaviour 369 group when compared with the lowest group (8). However, a recent study in UK Biobank 370 found little evidence of any association between hours spent watching television and the risk 371 of breast cancer (OR per 1 hour increase: 1.01, 95% CI: 0.99, 1.03) (9). In our analysis we 372 initially observed positive associations between hours of television watching and the risk of 373 breast cancer. However, these positive effect estimates were attenuated towards the null in our 374 multivariable MR models adjusting for other risk factors, particularly years of education. 375 Numerous observational studies have investigated the associations between sedentary 376 behaviours and colorectal cancer risk. Results from the most recent meta-analysis of case-

377 control and cohort studies reported a non-significant 10% risk increase for colorectal cancer

378 for the highest sedentary behaviour group when compared with the lowest group (RR=1.10, 379 95% CI: 0.96–1.26) (8). Television viewing time has been the most investigated sedentary 380 behaviour trait and positive associations have been found with colon cancer (9, 40). A recent 381 UK Biobank analysis reported that higher levels of television watching time were associated 382 with greater colon cancer risk (HR per 1-hour increase, 1.04, 95% CI: 1.01–1.07; P-383 value=0.016), but not rectal cancer (9). The same UK Biobank study found no association 384 between leisure computer use and colorectal cancer risk (9). Results from our univariable MR 385 analyses were generally consistent with this prior observational evidence, with positive effect 386 estimates found for television watching, and little evidence of an association between 387 computer use and colorectal cancer risk, except of rectal cancer. However, like our breast 388 results, these associations attenuated towards the null in multivariable MR models adjusted 389 for years of education and smoking (colorectal; television watching) or alcohol (rectal; 390 computer use). 391 We found little evidence of any associations between sedentary behaviours and 392 prostate cancer risk, consistent with prior observational evidence (9, 40). The null effects we 393 found were similar for overall and aggressive prostate cancer risk.

394 Strong genetic correlations have been reported between each of television watching (inverse) and computer use (positive) and years of education ($r_q^{TV} = -0.79$ and $r_q^{PC} = 0.53$) (16). 395 396 The low conditional F statistics in our multivariable models including the sedentary behaviour 397 traits with years of education provided a further indicator of strong correlations. A recent MR 398 study reported an inverse association between years of education and breast (OR, 0.89, 95% 399 CI: 0.83, 0.96; P-value = 0.001) and a positive association for prostate cancer (OR, 1.10, 95%400 CI: 1.01, 1.21; P-value = 0.035) (41). In agreement with that, we observed inverse effect 401 estimates for years of education in our multivariable models for breast and also for colorectal 402 cancer. An additional MR study found that higher educational attainment levels were further

403	inversely associated with smoking, BMI, and sedentary behaviours, and positively with
404	vigorous physical activity levels and alcohol consumption (42). Therefore, education may be
405	a proxy for overall lifestyle, with higher educated individuals practising healthier lifestyle
406	behaviours and actively participating in screening programs that lower their risk of
407	developing cancer (41). Additionally, traits like sedentary behaviours, education, smoking,
408	alcohol consumption, and obesity are correlated and it is therefore difficult to disentangle
409	their complex interrelationships. As an example, in our post-hoc analyses we found evidence
410	of education having a dual confounding and mediating role in the association between
411	television watching with breast and colorectal cancers.
412	The main strength of the current study is the use of large-scale summary genetic data
413	from consortia and the UK Biobank that allowed us to investigate the role of leisure sedentary
414	behaviours on risk of developing breast, colorectal, and prostate cancer. A limitation of our
415	study is that leisure sedentary behaviours were derived from self-reported questionnaires that
416	are prone to measurement error (43, 44). An alternative approach is to use genetic instruments
417	derived from objectively measured levels of physical activity using accelerometer data from
418	the UK Biobank. However, a current limitation is that the number of genetic instruments is
419	small as the GWAS on accelerometer data was analysed in a subset of 90,000 participants.
420	Analysing two highly correlated phenotypes together, like sedentary behaviours and years of
421	education may have introduced collinearity which leads to greater imprecision and possible
422	bias. Furthermore, caution is needed regarding the results from the analyses for leisure
423	computer use as the genetic instruments explained a very small proportion of the phenotypic
424	variance resulting in a low powered analysis. Also, our analyses focused solely on leisure
425	sedentary behaviours. The genetic correlation between television watching and objectively
426	measured sedentary behaviour in UK Biobank was weak while, the correlation for computer
427	use was higher $(r_g^{TV} = 0.14 \text{ and } r_g^{PC} = 0.46)$ (16). This can be at least partially explained from

428	the fact that accelerometers measure total but not domain-specific sedentary time (e.g.,
429	television watching) and that has been observed in previous observational studies (3, 45).
430	Therefore, our results cannot be generalised to overall sedentary behaviour. Finally, the
431	results cannot be generalised to diverse populations due to the lack of ancestral diversity in
432	UK Biobank.
433	In conclusion, we found that higher genetically predicted television watching time
434	increased risks of breast and colorectal cancer in univariable models. When we adjusted for
435	years of education in multivariable MR models, these positive effect estimates were no longer
436	present. However, these multivariable results should be interpreted cautiously as we detected
437	evidence of education having a dual confounding and mediating role in the associations
438	between television watching with risks of breast and colorectal cancer. Future analyses
439	utilising objective measures of exposure (e.g., accelerometers) and novel analytic frameworks
440	(e.g., target trial emulation) are required to provide new insights into the possible role of
441	sedentary behaviour in cancer development.

443 **Competing interests:**

444 The authors declare no competing interests.

445

- 446 **Disclaimer:** Where authors are identified as personnel of the International Agency for
- 447 Research on Cancer / World Health Organization, the authors alone are responsible for the
- views expressed in this article and they do not necessarily represent the decisions, policy or
- views of the International Agency for Research on Cancer / World Health Organization.

450

451 Data availability

452 The summary statistics used in this study are outlined in the supplementary materials.

453

454 Ethics approval

- 455 All analyses were conducted using summary-level data generated by previous studies that
- 456 have described their relevant ethical approvals.

457

458 Author contributions

- 459 NP contributed to the analysis and interpretation of data and draft of the manuscript. NK
- 460 contributed to the analysis and to the data acquisition. NM contributed to the
- 461 conceptualization, interpretation of data and methodology. KKT, RMM, SJL, BML
- 462 contributed to interpretation of data and methodology. UP contributed to the data acquisition.
- 463 NP, NK, ND, KKT, RMM, SJL, BML, MH, SSK, LL, RLM, LCS, RES, AIP, JCF, UP,
- 464 SCDS, MJG, and NM reviewed, contributed to, and approved the final version of the

465 manuscript.

466

467 Funding

- 468 This work is supported by a WCRF grant (WCRF_2020_019). RMM is supported by a
- 469 Cancer Research UK Programme Grant, the Integrative Cancer Epidemiology Programme
- 470 (C18281/A29019). RMM is a member of the MRC IEU which is supported by the Medical
- 471 Research Council and the University of Bristol (MC_UU_12013/1-9). RMM is supported by
- 472 the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre which
- 473 is funded by the National Institute for Health Research and is a partnership between
- 474 University Hospitals Bristol NHS Trust, Weston NHS Foundation Trust and the University of
- 475 Bristol. The views expressed in this publication are those of the author(s) and not necessarily
- those of the NIHR or the UK Department of Health and Social Care.
- 477 BML is supported by the Victorian Cancer Agency (MCRF-18005).
- 478 SJL is supported by a WCRF grant (WCRF_2020_019).
- 479 GECCO: Genetics and Epidemiology of Colorectal Cancer Consortium: National Cancer
- 480 Institute, National Institutes of Health, U.S. Department of Health and Human Services (U01
- 481 CA164930, U01 CA137088, R01 CA059045, R21 CA191312, R01201407).
- 482 Genotyping/Sequencing services were provided by the Center for Inherited Disease Research
- 483 (CIDR) contract number HHSN268201700006I and HHSN268201200008I. This research
- 484 was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA015704.
- 485 Scientific Computing Infrastructure at Fred Hutch funded by ORIP grant S10OD028685
- 486 ASTERISK: a Hospital Clinical Research Program (PHRC-BRD09/C) from the University
- 487 Hospital Center of Nantes (CHU de Nantes) and supported by the Regional Council of Pays
- 488 de la Loire, the Groupement des Entreprises Françaises dans la Lutte contre le Cancer
- 489 (GEFLUC), the Association Anne de Bretagne Génétique and the Ligue Régionale Contre le
- 490 Cancer (LRCC).
- 491 The ATBC Study is supported by the Intramural Research Program of the U.S. National
- 492 Cancer Institute, National Institutes of Health.

493	CLUE II funding was from the National Cancer Institute (U01 CA86308, Early Detection
494	Research Network; P30 CA006973), National Institute on Aging (U01 AG18033), and the
495	American Institute for Cancer Research. The content of this publication does not necessarily
496	reflect the views or policies of the Department of Health and Human Services, nor does
497	mention of trade names, commercial products, or organizations imply endorsement by the US
498	government. Maryland Cancer Registry (MCR) Cancer data was provided by the Maryland
499	Cancer Registry, Center for Cancer Prevention and Control, Maryland Department of Health,
500	with funding from the State of Maryland and the Maryland Cigarette Restitution Fund. The
501	collection and availability of cancer registry data is also supported by the Cooperative
502	Agreement NU58DP006333, funded by the Centers for Disease Control and Prevention. Its
503	contents are solely the responsibility of the authors and do not necessarily represent the
504	official views of the Centers for Disease Control and Prevention or the Department of Health
505	and Human Services.
506	ColoCare: This work was supported by the National Institutes of Health (grant numbers R01
507	CA189184 (Li/Ulrich), U01 CA206110 (Ulrich/Li/Siegel/Figueireido/Colditz,
508	2P30CA015704-40 (Gilliland), R01 CA207371 (Ulrich/Li)), the Matthias Lackas-
509	Foundation, the German Consortium for Translational Cancer Research, and the EU
510	TRANSCAN initiative.
511	The Colon Cancer Family Registry (CCFR, www.coloncfr.org) is supported in part by
512	funding from the National Cancer Institute (NCI), National Institutes of Health (NIH) (award
513	U01 CA167551). Support for case ascertainment was provided in part from the Surveillance,
514	Epidemiology, and End Results (SEER) Program and the following U.S. state cancer
515	registries: AZ, CO, MN, NC, NH; and by the Victoria Cancer Registry (Australia) and
516	Ontario Cancer Registry (Canada). The CCFR Set-1 (Illumina 1M/1M-Duo) was supported
517	by NIH awards U01 CA122839 and R01 CA143247 (to GC). The CCFR Set-3 (Affymetrix

518	Axiom CORECT Set array) was supported by NIH award U19 CA148107 and R01 CA81488
519	(to SBG). The CCFR Set-4 (Illumina OncoArray 600K SNP array) was supported by NIH
520	award U19 CA148107 (to SBG) and by the Center for Inherited Disease Research (CIDR),
521	which is funded by the NIH to the Johns Hopkins University, contract number
522	HHSN268201200008I. Additional funding for the The content of this manuscript does not
523	necessarily reflect the views or policies of the NCI, NIH or any of the collaborating centers in
524	the Colon Cancer Family Registry (CCFR), nor does mention of trade names, commercial
525	products, or organizations imply endorsement by the US Government, any cancer registry, or
526	the CCFR.
527	COLON: The COLON study is sponsored by Wereld Kanker Onderzoek Fonds, including
528	funds from grant 2014/1179 as part of the World Cancer Research Fund International Regular
529	Grant Programme, by Alpe d'Huzes and the Dutch Cancer Society (UM 2012–5653, UW
530	2013-5927, UW2015-7946), and by TRANSCAN (JTC2012-MetaboCCC, JTC2013-
531	FOCUS). The Nqplus study is sponsored by a ZonMW investment grant (98-10030); by
532	PREVIEW, the project PREVention of diabetes through lifestyle intervention and population
533	studies in Europe and around the World (PREVIEW) project which received funding from the
534	European Union Seventh Framework Programme (FP7/2007–2013) under grant no. 312057;
535	by funds from TI Food and Nutrition (cardiovascular health theme), a public-private
536	partnership on precompetitive research in food and nutrition; and by FOODBALL, the Food
537	Biomarker Alliance, a project from JPI Healthy Diet for a Healthy Life.
538	Colorectal Cancer Transdisciplinary (CORECT) Study: The CORECT Study was supported
539	by the National Cancer Institute, National Institutes of Health (NCI/NIH), U.S. Department of
540	Health and Human Services (grant numbers U19 CA148107, R01 CA81488, P30 CA014089,
541	R01 CA197350,; P01 CA196569; R01 CA201407) and National Institutes of Environmental
542	Health Sciences, National Institutes of Health (grant number T32 ES013678).

543 CORSA: "Österreichische Nationalbank Jubiläumsfondsprojekt" (12511) and Austrian

- 544 Research Funding Agency (FFG) grant 829675.
- 545 CPS-II: The American Cancer Society funds the creation, maintenance, and updating of the
- 546 Cancer Prevention Study-II (CPS-II) cohort. This study was conducted with Institutional
- 547 Review Board approval.
- 548 CRCGEN: Colorectal Cancer Genetics & Genomics, Spanish study was supported by
- 549 Instituto de Salud Carlos III, co-funded by FEDER funds –a way to build Europe– (grants
- 550 PI14-613 and PI09-1286), Agency for Management of University and Research Grants
- 551 (AGAUR) of the Catalan Government (grant 2017SGR723), and Junta de Castilla y León
- (grant LE22A10-2). Sample collection of this work was supported by the Xarxa de Bancs de
- 553 Tumors de Catalunya sponsored by Pla Director d'Oncología de Catalunya (XBTC),
- 554 Plataforma Biobancos PT13/0010/0013 and ICOBIOBANC, sponsored by the Catalan
- 555 Institute of Oncology.
- 556 Czech Republic CCS: This work was supported by the Czech Science Foundation (20-
- 557 03997S) and by the Grant Agency of the Ministry of Health of the Czech Republic (grants
- 558 NV18/03/00199 and NU21-07-00247).
- 559 DACHS: This work was supported by the German Research Council (BR 1704/6-1, BR
- 560 1704/6-3, BR 1704/6-4, CH 117/1-1, HO 5117/2-1, HE 5998/2-1, KL 2354/3-1, RO 2270/8-1
- and BR 1704/17-1), the Interdisciplinary Research Program of the National Center for Tumor
- 562 Diseases (NCT), Germany, and the German Federal Ministry of Education and Research
- 563 (01KH0404, 01ER0814, 01ER0815, 01ER1505A and 01ER1505B).
- 564 DALS: National Institutes of Health (R01 CA48998 to M. L. Slattery).
- 565 EDRN: This work is funded and supported by the NCI, EDRN Grant (U01CA152753).
- 566 EPIC: The coordination of EPIC is financially supported by the European Commission
- 567 (DGSANCO) and the International Agency for Research on Cancer. The national cohorts are

568	supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave
569	Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la
570	Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research
571	Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe,
572	Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research
573	(Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul
574	Cancro-AIRCItaly and National Research Council (Italy); Dutch Ministry of Public Health,
575	Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch
576	Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund
577	(WCRF), Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk,
578	Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Health
579	Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional
580	Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC
581	(RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council and County
582	Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk;
583	C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to
584	EPIC-Norfolk, MR/M012190/1 to EPICOxford) (United Kingdom).
585	The EPIC-Norfolk study (https://doi.org/10.22025/2019.10.105.00004) has received funding
586	from the Medical Research Council (MR/N003284/1 and MC-UU_12015/1) and Cancer
587	Research UK (C864/A14136). The genetics work in the EPIC-Norfolk study was funded by
588	the Medical Research Council (MC_PC_13048). Metabolite measurements in the EPIC-
589	Norfolk study were supported by the MRC Cambridge Initiative in Metabolic Science
590	(MR/L00002/1) and the Innovative Medicines Initiative Joint Undertaking under EMIF grant
591	agreement no. 115372.

- 592 EPICOLON: This work was supported by grants from Fondo de Investigación
- 593 Sanitaria/FEDER (PI08/0024, PI08/1276, PS09/02368, PI11/00219, PI11/00681, PI14/00173,
- 594 PI14/00230, PI17/00509, 17/00878, PI20/00113, PI20/00226, Acción Transversal de Cáncer),
- 595 Xunta de Galicia (PGIDIT07PXIB9101209PR), Ministerio de Economia y Competitividad
- 596 (SAF07-64873, SAF 2010-19273, SAF2014-54453R), Fundación Científica de la Asociación
- 597 Española contra el Cáncer (GCB13131592CAST), Beca Grupo de Trabajo "Oncología" AEG
- 598 (Asociación Española de Gastroenterología), Fundación Privada Olga Torres, FP7 CHIBCHA
- 599 Consortium, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR, Generalitat de
- 600 Catalunya, 2014SGR135, 2014SGR255, 2017SGR21, 2017SGR653), Catalan Tumour Bank
- 601 Network (Pla Director d'Oncologia, Generalitat de Catalunya), PERIS (SLT002/16/00398,
- 602 Generalitat de Catalunya), CERCA Programme (Generalitat de Catalunya) and COST Actions
- 603 BM1206 and CA17118. CIBERehd is funded by the Instituto de Salud Carlos III.
- 604 ESTHER/VERDI. This work was supported by grants from the Baden-Württemberg Ministry
- of Science, Research and Arts and the German Cancer Aid.
- 606 Harvard cohorts (HPFS, NHS, PHS): HPFS is supported by the National Institutes of Health
- 607 (P01 CA055075, UM1 CA167552, U01 CA167552, R01 CA137178, R01 CA151993, R35
- 608 CA197735, K07 CA190673, and P50 CA127003), NHS by the National Institutes of Health
- 609 (R01 CA137178, P01 CA087969, UM1 CA186107, R01 CA151993, R35 CA197735,
- 610 K07CA190673, and P50 CA127003) and PHS by the National Institutes of Health (R01
- 611 CA042182).
- 612 Hawaii Adenoma Study: NCI grants R01 CA72520.
- 613 HCES-CRC: the Hwasun Cancer Epidemiology Study–Colon and Rectum Cancer (HCES-
- 614 CRC; grants from Chonnam National University Hwasun Hospital, HCRI21019).
- 615 Kentucky: This work was supported by the following grant support: Clinical Investigator
- 616 Award from Damon Runyon Cancer Research Foundation (CI-8); NCI R01CA136726.

- 617 LCCS: The Leeds Colorectal Cancer Study was funded by the Food Standards Agency and
- 618 Cancer Research UK Programme Award (C588/A19167).
- 619 Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth
- and Cancer Council Victoria. The MCCS was further augmented by Australian National
- Health and Medical Research Council grants 209057, 396414 and 1074383 and by
- 622 infrastructure provided by Cancer Council Victoria. Cases and their vital status were
- ascertained through the Victorian Cancer Registry and the Australian Institute of Health and
- 624 Welfare, including the National Death Index and the Australian Cancer Database.
- 625 Multiethnic Cohort (MEC) Study: National Institutes of Health (R37 CA54281, P01
- 626 CA033619, R01 CA063464 and U01 CA164973).
- 627 MECC: This work was supported by the National Institutes of Health, U.S. Department of
- 628 Health and Human Services (R01 CA81488 to SBG and GR).
- 629 MSKCC: The work at Sloan Kettering in New York was supported by the Robert and Kate
- 630 Niehaus Center for Inherited Cancer Genomics and the Romeo Milio Foundation. Moffitt:
- 631 This work was supported by funding from the National Institutes of Health (grant numbers
- 632 R01 CA189184, P30 CA076292), Florida Department of Health Bankhead-Coley Grant
- 633 09BN-13, and the University of South Florida Oehler Foundation. Moffitt contributions were
- 634 supported in part by the Total Cancer Care Initiative, Collaborative Data Services Core, and
- 635 Tissue Core at the H. Lee Moffitt Cancer Center & Research Institute, a National Cancer
- 636 Institute-designated Comprehensive Cancer Center (grant number P30 CA076292).
- 637 NCCCS I & II: We acknowledge funding support for this project from the National Institutes
- 638 of Health, R01 CA66635 and P30 DK034987.
- 639 NFCCR: This work was supported by an Interdisciplinary Health Research Team award from
- 640 the Canadian Institutes of Health Research (CRT 43821); the National Institutes of Health,
- 641 U.S. Department of Health and Human Serivces (U01 CA74783); and National Cancer

642 Ir	nstitute of Car	nada grants (18223 and	18226).	The authors	wish to a	acknowle	edge tl	he
--------	-----------------	---------------	-----------	---------	-------------	-----------	----------	---------	----

- 643 contribution of Alexandre Belisle and the genotyping team of the McGill University and
- 644 Génome Québec Innovation Centre, Montréal, Canada, for genotyping the Sequenom panel in
- the NFCCR samples. Funding was provided to Michael O. Woods by the Canadian Cancer
- 646 Society Research Institute.
- 647 NSHDS: Swedish Research Council; Swedish Cancer Society; Cutting-Edge Research Grant
- and other grants from Region Västerbotten; Knut and Alice Wallenberg Foundation; Lion's
- 649 Cancer Research Foundation at Umeå University; the Cancer Research Foundation in
- 650 Northern Sweden; and the Faculty of Medicine, Umeå University, Umeå, Sweden.
- 651 OSUMC: OCCPI funding was provided by Pelotonia and HNPCC funding was provided by
- 652 the NCI (CA16058 and CA67941).
- 653 PLCO: Intramural Research Program of the Division of Cancer Epidemiology and Genetics
- and supported by contracts from the Division of Cancer Prevention, National Cancer Institute,
- NIH, DHHS. Funding was provided by National Institutes of Health (NIH), Genes,
- 656 Environment and Health Initiative (GEI) Z01 CP 010200, NIH U01 HG004446, and NIH GEI
- 657 U01 HG 004438.
- 658 SEARCH: The University of Cambridge has received salary support in respect of PDPP from
- the NHS in the East of England through the Clinical Academic Reserve. Cancer Research UK
- 660 (C490/A16561); the UK National Institute for Health Research Biomedical Research Centres
- at the University of Cambridge.
- 662 SELECT: Research reported in this publication was supported in part by the National Cancer
- 663 Institute of the National Institutes of Health under Award Numbers U10 CA37429 (CD
- Blanke), and UM1 CA182883 (CM Tangen/IM Thompson). The content is solely the
- responsibility of the authors and does not necessarily represent the official views of the
- 666 National Institutes of Health.

- 667 SMS and REACH: This work was supported by the National Cancer Institute (grant P01
- 668 CA074184 to J.D.P. and P.A.N., grants R01 CA097325, R03 CA153323, and K05 CA152715
- to P.A.N., and the National Center for Advancing Translational Sciences at the National
- 670 Institutes of Health (grant KL2 TR000421 to A.N.B.-H.)
- 671 The Swedish Low-risk Colorectal Cancer Study: The study was supported by grants from the
- 672 Swedish research council; K2015-55X-22674-01-4, K2008-55X-20157-03-3, K2006-72X-
- 673 20157-01-2 and the Stockholm County Council (ALF project).
- 674 Swedish Mammography Cohort and Cohort of Swedish Men: This work is supported by the
- 675 Swedish Research Council /Infrastructure grant, the Swedish Cancer Foundation, and the
- 676 Karolinska Institute's Distinguished Professor Award to Alicja Wolk.
- 677 UK Biobank: This research has been conducted using the UK Biobank Resource under
- 678 Application Number 8614
- 679 VITAL: National Institutes of Health (K05 CA154337).
- 680 WHI: The WHI program is funded by the National Heart, Lung, and Blood Institute, National
- 681 Institutes of Health, U.S. Department of Health and Human Services through contracts
- 682 HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
- 683 HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C.
- 684

685 Acknowledgements

- 686 The breast cancer genome-wide association analyses for BCAC and CIMBA were supported
- 687 by Cancer Research UK (PPRPGM-Nov20\100002, C1287/A10118, C1287/A16563,
- 688 C1287/A10710, C12292/A20861, C12292/A11174, C1281/A12014, C5047/A8384,
- 689 C5047/A15007, C5047/A10692, C8197/A16565) and the Gray Foundation, The National
- 690 Institutes of Health (CA128978, X01HG007492- the DRIVE consortium), the
- 691 PERSPECTIVE project supported by the Government of Canada through Genome Canada

692	and the Canadian	Institutes of He	ealth Research ((grant GPH-1	.29344) and	d the Ministère de
-----	------------------	------------------	------------------	--------------	-------------	--------------------

- 693 l'Économie, Science et Innovation du Québec through Genome Québec and the PSRSIIRI-
- 694 701 grant, the Quebec Breast Cancer Foundation, the European Community's Seventh
- 695 Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175)
- 696 (COGS), the European Union's Horizon 2020 Research and Innovation Programme (634935
- 697 and 633784), the Post-Cancer GWAS initiative (U19 CA148537, CA148065 and CA148112 -
- the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian
- 699 Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer
- 700 (CRN-87521), the Komen Foundation for the Cure, the Breast Cancer Research Foundation
- and the Ovarian Cancer Research Fund. All studies and funders are listed in Zhang H et al
- 702 (Nat Genet, 2020).
- 703 ASTERISK: We are very grateful to Dr. Bruno Buecher without whom this project would not
- have existed. We also thank all those who agreed to participate in this study, including the
- patients and the healthy control persons, as well as all the physicians, technicians and
- 706 students.
- 707 CCFR: The Colon CFR graciously thanks the generous contributions of their study
- 708 participants, dedication of study staff, and the financial support from the U.S. National Cancer
- 709 Institute, without which this important registry would not exist. The authors would like to
- thank the study participants and staff of the Seattle Colon Cancer Family Registry and the
- 711 Hormones and Colon Cancer study (CORE Studies).
- 712 CLUE II: We thank the participants of Clue II and appreciate the continued efforts of the staff
- 713 at the Johns Hopkins George W. Comstock Center for Public Health Research and Prevention
- 714 in the conduct of the Clue II Cohort Study.

715 COLON and NQplus: the authors would like to thank the COLON and NQplus investigators

- 716 at Wageningen University & Research and the involved clinicians in the participating
- 717 hospitals.
- 718 CORSA: We kindly thank all those who contributed to the screening project Burgenland
- against CRC. Furthermore, we are grateful to Doris Mejri and Monika Hunjadi for laboratory
- 720 assistance.
- 721 CPS-II: The authors thank the CPS-II participants and Study Management Group for their
- invaluable contributions to this research. The authors would also like to acknowledge the
- contribution to this study from central cancer registries supported through the Centers for
- 724 Disease Control and Prevention National Program of Cancer Registries, and cancer registries
- supported by the National Cancer Institute Surveillance Epidemiology and End Results
- 726 program.
- 727 Czech Republic CCS: We are thankful to all clinicians in major hospitals in the Czech
- 728 Republic, without whom the study would not be practicable. We are also sincerely grateful to
- all patients participating in this study.
- 730 DACHS: We thank all participants and cooperating clinicians, and Ute Handte-Daub, Utz
- 731 Benscheid, Muhabbet Celik and Ursula Eilber for excellent technical assistance.
- EDRN: We acknowledge all the following contributors to the development of the resource:
- 733 University of Pittsburgh School of Medicine, Division of Gastroenterology, Hepatology and
- 734 Nutrition: Lynda Dzubinski; University of Pittsburgh School of Medicine, Department of
- 735 Pathology: Pittsburgh Biospecimen Core; and University of Pittsburgh School of Medicine,
- 736 Department of Biomedical Informatics.
- 737 EPIC: Where authors are identified as personnel of the International Agency for Research on
- 738 Cancer/World Health Organization, the authors alone are responsible for the views expressed

in this article and they do not necessarily represent the decisions, policy or views of the

740 International Agency for Research on Cancer/World Health Organization.

741 The EPIC-Norfolk study: we are grateful to all the participants who have been part of the

742 project and to the many members of the study teams at the University of Cambridge who have

rabled this research.

744 EPICOLON: We are sincerely grateful to all patients participating in this study who were

recruited as part of the EPICOLON project. We acknowledge the Spanish National DNA

746 Bank, Biobank of Hospital Clínic–IDIBAPS and Biobanco Vasco for the availability of the

samples. The work was carried out (in part) at the Esther Koplowitz Centre, Barcelona.

748 Harvard cohorts (HPFS, NHS, PHS): The study protocol was approved by the institutional

review boards of the Brigham and Women's Hospital and Harvard T.H. Chan School of

750 Public Health, and those of participating registries as required. We acknowledge Channing

751 Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital as

home of the NHS We would like to thank the participants and staff of the HPFS, NHS and

753 PHS for their valuable contributions as well as the following state cancer registries for their

help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI,

NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors

assume full responsibility for analyses and interpretation of these data.

757 Interval: A complete list of the investigators and contributors to the INTERVAL trial is

758 provided in reference (32). The academic coordinating centre would like to thank blood donor

centre staff and blood donors for participating in the INTERVAL trial.

760

761 Kentucky: We would like to acknowledge the staff at the Kentucky Cancer Registry.

762 LCCS: We acknowledge the contributions of Jennifer Barrett, Robin Waxman, Gillian Smith

and Emma Northwood in conducting this study.

- 764 NCCCS I & II: We would like to thank the study participants, and the NC Colorectal Cancer
- 765 Study staff.
- 766 NSHDS investigators thank the Biobank Research Unit at Umeå University, the Västerbotten
- 767 Intervention Programme, the Northern Sweden MONICA study and Region Västerbotten for
- 768 providing data and samples and acknowledge the contribution from Biobank Sweden,
- supported by the Swedish Research Council (VR 2017-00650).
- 770 PLCO: The authors thank the PLCO Cancer Screening Trial screening center investigators
- and the staff from Information Management Services Inc and Westat Inc. Most importantly,
- we thank the study participants for their contributions that made this study possible.
- **773** SEARCH: We thank the SEARCH team.
- 774 SELECT: We thank the research and clinical staff at the sites that participated on SELECT
- study, without whom the trial would not have been successful. We are also grateful to the
- 776 35,533 dedicated men who participated in SELECT.
- 777 UK Biobank: We would like to thank the participants and researchers UK Biobank for their
- 778 participation and acquisition of data.
- 779 WHI: The authors thank the WHI investigators and staff for their dedication, and the study
- 780 participants for making the program possible. A full listing of WHI investigators can be found
- 781 at:
- 782 http://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investiga
- 783 tor%20Short%20List.pdf
- 784

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.

2. Tremblay MS, Aubert S, Barnes JD, Saunders TJ, Carson V, Latimer-Cheung AE, Chastin SFM, Altenburg TM, Chinapaw MJM, Participants STCP. Sedentary Behavior Research Network (SBRN) - Terminology Consensus Project process and outcome. Int J Behav Nutr Phys Act. 2017;14(1):75.

3. Prince SA, LeBlanc AG, Colley RC, Saunders TJ. Measurement of sedentary behaviour in population health surveys: a review and recommendations. PeerJ. 2017;5:e4130.

4. Yang L, Cao C, Kantor ED, Nguyen LH, Zheng X, Park Y, Giovannucci EL, Matthews CE, Colditz GA, Cao Y. Trends in Sedentary Behavior Among the US Population, 2001-2016. JAMA. 2019;321(16):1587-97.

5. British heart foundation. Physical Inactivity and Sedentary Behaviour Report 2017 2017 [Available from:

https://www.bhf.org.uk/informationsupport/publications/statistics/physical-inactivity-report-2017.

6. Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, Alter DA. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. Ann Intern Med. 2015;162(2):123-32.

7. Patterson R, McNamara E, Tainio M, de Sa TH, Smith AD, Sharp SJ, Edwards P, Woodcock J, Brage S, Wijndaele K. Sedentary behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident type 2 diabetes: a systematic review and dose response meta-analysis. Eur J Epidemiol. 2018;33(9):811-29.

8. Lynch BM, Mahmood S, Boyle T. Sedentary Behaviour and Cancer. In: Leitzmann MF, Jochem C, Schmid D, editors. Sedentary Behaviour Epidemiology. Cham: Springer International Publishing; 2018. p. 245-98.

9. Hunter RF, Murray JM, Coleman HG. The association between recreational screen time and cancer risk: findings from the UK Biobank, a large prospective cohort study. Int J Behav Nutr Phys Act. 2020;17(1):97.

10. Lawlor DA, Davey Smith G, Kundu D, Bruckdorfer KR, Ebrahim S. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? Lancet. 2004;363(9422):1724-7.

11. Davey Smith G, Ebrahim S. Epidemiology--is it time to call it a day? Int J Epidemiol. 2001;30(1):1-11.

12. Prince SA, Reed JL, McFetridge C, Tremblay MS, Reid RD. Correlates of sedentary behaviour in adults: a systematic review. Obes Rev. 2017;18(8):915-35.

13. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1-22.

14. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133-63.

15. Gao Y, Mi J, Liu Z, Song Q. Leisure Sedentary Behavior and Risk of Lung Cancer: A Two-Sample Mendelian Randomization Study and Mediation Analysis. Front Genet. 2021;12:763626.

16. van de Vegte YJ, Said MA, Rienstra M, van der Harst P, Verweij N. Genome-wide association studies and Mendelian randomization analyses for leisure sedentary behaviours. Nat Commun. 2020;11(1):1770.

17. Huyghe JR, Bien SA, Harrison TA, Kang HM, Chen S, Schmit SL, Conti DV, Qu C, Jeon J, Edlund CK, Greenside P, Wainberg M, Schumacher FR, Smith JD, Levine DM, Nelson SC, Sinnott-Armstrong NA, Albanes D, Alonso MH, Anderson K, Arnau-Collell C, Arndt V, Bamia C, Banbury BL, Baron JA, Berndt SI, Bezieau S, Bishop DT, Boehm J,

Boeing H, Brenner H, Brezina S, Buch S, Buchanan DD, Burnett-Hartman A, Butterbach K, Caan BJ, Campbell PT, Carlson CS, Castellvi-Bel S, Chan AT, Chang-Claude J, Chanock SJ, Chirlague MD, Cho SH, Connolly CM, Cross AJ, Cuk K, Curtis KR, de la Chapelle A, Doheny KF, Duggan D, Easton DF, Elias SG, Elliott F, English DR, Feskens EJM, Figueiredo JC, Fischer R, FitzGerald LM, Forman D, Gala M, Gallinger S, Gauderman WJ, Giles GG, Gillanders E, Gong J, Goodman PJ, Grady WM, Grove JS, Gsur A, Gunter MJ, Haile RW, Hampe J, Hampel H, Harlid S, Hayes RB, Hofer P, Hoffmeister M, Hopper JL, Hsu WL, Huang WY, Hudson TJ, Hunter DJ, Ibanez-Sanz G, Idos GE, Ingersoll R, Jackson RD, Jacobs EJ, Jenkins MA, Joshi AD, Joshu CE, Keku TO, Key TJ, Kim HR, Kobayashi E, Kolonel LN, Kooperberg C, Kuhn T, Kury S, Kweon SS, Larsson SC, Laurie CA, Le Marchand L, Leal SM, Lee SC, Lejbkowicz F, Lemire M, Li CI, Li L, Lieb W, Lin Y, Lindblom A, Lindor NM, Ling H, Louie TL, Mannisto S, Markowitz SD, Martin V, Masala G, McNeil CE, Melas M, Milne RL, Moreno L, Murphy N, Myte R, Naccarati A, Newcomb PA, Offit K, Ogino S, Onland-Moret NC, Pardini B, Parfrey PS, Pearlman R, Perduca V, Pharoah PDP, Pinchev M, Platz EA, Prentice RL, Pugh E, Raskin L, Rennert G, Rennert HS, Riboli E, Rodriguez-Barranco M, Romm J, Sakoda LC, Schafmayer C, Schoen RE, Seminara D, Shah M, Shelford T, Shin MH, Shulman K, Sieri S, Slattery ML, Southey MC, Stadler ZK, Stegmaier C, Su YR, Tangen CM, Thibodeau SN, Thomas DC, Thomas SS, Toland AE, Trichopoulou A. Ulrich CM, Van Den Berg DJ, van Duijnhoven FJB, Van Guelpen B, van Kranen H, Vijai J, Visvanathan K, Vodicka P, Vodickova L, Vymetalkova V, Weigl K, Weinstein SJ, White E, Win AK, Wolf CR, Wolk A, Woods MO, Wu AH, Zaidi SH, Zanke BW, Zhang Q, Zheng W, Scacheri PC, Potter JD, Bassik MC, Kundaje A, Casey G, Moreno V, Abecasis GR, Nickerson DA, Gruber SB, Hsu L, Peters U. Discovery of common and rare genetic risk variants for colorectal cancer. Nat Genet. 2019;51(1):76-87. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, 18. Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM, Jr., Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordstrom T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gomez-Caamano A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castano-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Roder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddig A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA, Profile S, Australian Prostate Cancer B, Study I, Canary PI, Breast, Prostate Cancer Cohort C, Consortium P, Cancer of the Prostate in S. Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility L, Genetic A, Mechanisms in Oncology /Elucidating Loci Involved in Prostate Cancer Susceptibility C. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50(7):928-36.

19. Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, O'Mara TA, Zhao N, Bolla MK, Dunning AM, Dennis J, Wang Q, Ful ZA, Aittomaki K, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Arun BK, Auer PL, Azzollini J, Barrowdale D, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bialkowska K, Blanco A, Blomgvist C, Bogdanova NV, Bojesen SE, Bonanni B, Bondavalli D, Borg A, Brauch H, Brenner H, Briceno I, Broeks A, Brucker SY, Bruning T, Burwinkel B, Buys SS, Byers H, Caldes T, Caligo MA, Calvello M, Campa D, Castelao JE, Chang-Claude J, Chanock SJ, Christiaens M, Christiansen H, Chung WK, Claes KBM, Clarke CL, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Diez O, Domchek SM, Dork T, Dwek M, Eccles DM, Ekici AB, Evans DG, Fasching PA, Figueroa J, Foretova L, Fostira F, Friedman E, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Saenz JA, Gaudet MM, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Gonzalez-Neira A, Greene MH, Gronwald J, Guenel P, Haberle L, Hahnen E, Haiman CA, Hake CR, Hall P, Hamann U, Harkness EF, Heemskerk-Gerritsen BAM, Hillemanns P, Hogervorst FBL, Holleczek B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huebner H, Hulick PJ, Imyanitov EN, kConFab I, Investigators A, Isaacs C, Izatt L, Jager A, Jakimovska M, Jakubowska A, James P, Janavicius R, Janni W, John EM, Jones ME, Jung A, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khan S, Khusnutdinova E, Kitahara CM, Ko YD, Konstantopoulou I, Koppert LB, Koutros S, Kristensen VN, Laenkholm AV, Lambrechts D, Larsson SC, Laurent-Puig P, Lazaro C, Lazarova E, Lejbkowicz F, Leslie G, Lesueur F, Lindblom A, Lissowska J, Lo WY, Loud JT, Lubinski J, Lukomska A, MacInnis RJ, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Matricardi L, McGuffog L, McLean C, Mebirouk N, Meindl A, Menon U, Miller A, Mingazheva E, Montagna M, Mulligan AM, Mulot C, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Nielsen FC, Nikitina-Zake L, Nodora J, Offit K, Olah E, Olopade OI, Olsson H, Orr N, Papi L, Papp J, Park-Simon TW, Parsons MT, Peissel B, Peixoto A, Peshkin B, Peterlongo P, Peto J, Phillips KA, Piedmonte M, Plaseska-Karanfilska D, Prajzendanc K, Prentice R, Prokofyeva D, Rack B, Radice P, Ramus SJ, Rantala J, Rashid MU, Rennert G, Rennert HS, Risch HA, Romero A, Rookus MA, Rubner M, Rudiger T, Saloustros E, Sampson S, Sandler DP, Sawyer EJ, Scheuner MT, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schottker B, Schurmann P, Senter L, Sharma P, Sherman ME, Shu XO, Singer CF, Smichkoska S, Soucy P, Southey MC, Spinelli JJ, Stone J, Stoppa-Lyonnet D, Study E, Collaborators GS, Swerdlow AJ, Szabo CI, Tamimi RM, Tapper WJ, Taylor JA, Teixeira MR, Terry M, Thomassen M, Thull DL, Tischkowitz M, Toland AE, Tollenaar R, Tomlinson I, Torres D, Troester MA, Truong T, Tung N, Untch M, Vachon CM, van den Ouweland AMW, van der Kolk LE, van Veen EM, vanRensburg EJ, Vega A, Wappenschmidt B, Weinberg CR, Weitzel JN, Wildiers H, Wingvist R, Wolk A, Yang XR, Yannoukakos D, Zheng W, Zorn KK, Milne RL, Kraft P, Simard J, Pharoah PDP, Michailidou K, Antoniou AC, Schmidt MK, Chenevix-Trench G, Easton DF, Chatteriee N, Garcia-Closas M. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet. 2020:52(6):572-81.

20. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013;42(5):1497-501.

21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ. 2003;327(7414):557-60.

22. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017;36(11):1783-802.

23. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-25.

24. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377-89.

25. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016;40(4):304-14.

26. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693-8.

27. Botteri E, Borroni E, Sloan EK, Bagnardi V, Bosetti C, Peveri G, Santucci C, Specchia C, van den Brandt P, Gallus S, Lugo A. Smoking and Colorectal Cancer Risk, Overall and by Molecular Subtypes: A Meta-Analysis. Am J Gastroenterol. 2020;115(12):1940-9.

28. Macacu A, Autier P, Boniol M, Boyle P. Active and passive smoking and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat. 2015;154(2):213-24.

29. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, Scotti L, Jenab M, Turati F, Pasquali E, Pelucchi C, Galeone C, Bellocco R, Negri E, Corrao G, Boffetta P, La Vecchia C. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112(3):580-93.

Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, Yengo L, 30. Ferreira T, Marouli E, Ji Y, Yang J, Jones S, Beaumont R, Croteau-Chonka DC, Winkler TW, Consortium G, Hattersley AT, Loos RJF, Hirschhorn JN, Visscher PM, Frayling TM, Yaghootkar H, Lindgren CM. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. Hum Mol Genet. 2019;28(1):166-74. 31. Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M, Nguyen-Viet TA, Bowers P, Sidorenko J, Karlsson Linner R, Fontana MA, Kundu T, Lee C, Li H, Li R, Royer R, Timshel PN, Walters RK, Willoughby EA, Yengo L, and Me Research T, Cogent, Social Science Genetic Association C, Alver M, Bao Y, Clark DW, Day FR, Furlotte NA, Joshi PK, Kemper KE, Kleinman A, Langenberg C, Magi R, Trampush JW, Verma SS, Wu Y, Lam M, Zhao JH, Zheng Z, Boardman JD, Campbell H, Freese J, Harris KM, Hayward C, Herd P, Kumari M, Lencz T, Luan J, Malhotra AK, Metspalu A, Milani L, Ong KK, Perry JRB, Porteous DJ, Ritchie MD, Smart MC, Smith BH, Tung JY, Wareham NJ, Wilson JF, Beauchamp JP, Conley DC, Esko T, Lehrer SF, Magnusson PKE, Oskarsson S, Pers TH, Robinson MR, Thom K, Watson C, Chabris CF, Meyer MN, Laibson DI, Yang J, Johannesson M, Koellinger PD, Turley P, Visscher PM, Benjamin DJ, Cesarini D. Gene

discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nat Genet. 2018;50(8):1112-21.

32. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, Datta G, Davila-Velderrain J, McGuire D, Tian C, Zhan X, and Me Research T, Psychiatry HA-I, Choquet H, Docherty AR, Faul JD, Foerster JR, Fritsche LG, Gabrielsen ME, Gordon SD, Haessler J, Hottenga JJ, Huang H, Jang SK, Jansen PR, Ling Y, Magi R, Matoba N, McMahon G, Mulas A, Orru V, Palviainen T, Pandit A, Reginsson GW, Skogholt AH, Smith JA, Taylor AE, Turman C, Willemsen G, Young H, Young KA, Zajac GJM, Zhao W, Zhou W, Bjornsdottir G, Boardman JD, Boehnke M, Boomsma DI, Chen C, Cucca F, Davies GE, Eaton CB, Ehringer MA, Esko T, Fiorillo E, Gillespie NA, Gudbjartsson DF, Haller T, Harris KM, Heath AC, Hewitt JK, Hickie IB, Hokanson JE, Hopfer CJ, Hunter DJ, Iacono WG, Johnson EO, Kamatani Y, Kardia SLR, Keller MC, Kellis M, Kooperberg C, Kraft P, Krauter KS, Laakso M, Lind PA, Loukola A, Lutz SM, Madden PAF, Martin NG, McGue M, McQueen MB, Medland SE, Metspalu A, Mohlke KL, Nielsen JB, Okada Y, Peters U, Polderman TJC, Posthuma D, Reiner AP, Rice JP, Rimm E, Rose RJ, Runarsdottir V, Stallings MC, Stancakova A, Stefansson H, Thai KK, Tindle HA, Tyrfingsson T, Wall TL, Weir DR, Weisner C, Whitfield JB, Winsvold BS, Yin J, Zuccolo L, Bierut LJ, Hveem K, Lee JJ, Munafo MR, Saccone NL, Willer CJ, Cornelis MC, David SP, Hinds DA, Jorgenson E, Kaprio J, Stitzel JA, Stefansson K, Thorgeirsson TE, Abecasis G, Liu DJ, Vrieze S. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat Genet. 2019;51(2):237-44.

33. Wootton RE, Richmond RC, Stuijfzand BG, Lawn RB, Sallis HM, Taylor GMJ, Hemani G, Jones HJ, Zammit S, Davey Smith G, Munafo MR. Evidence for causal effects of

lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study. Psychol Med. 2020;50(14):2435-43.

34. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol. 2019;48(3):713-27.

35. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46(6):1734-9.

36. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM, Relton C, Martin RM, Davey Smith G, Gaunt TR, Haycock PC. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7.

37. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13(11):e1007081.

38. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, Timpson NJ, Higgins JPT, Dimou N, Langenberg C, Loder EW, Golub RM, Egger M, Davey Smith G, Richards JB. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ. 2021;375:n2233.

39. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-21.

40. Schmid D, Leitzmann MF. Television viewing and time spent sedentary in relation to cancer risk: a meta-analysis. J Natl Cancer Inst. 2014;106(7).

41. Yuan S, Xiong Y, Michaelsson M, Michaelsson K, Larsson SC. Genetically predicted education attainment in relation to somatic and mental health. Sci Rep. 2021;11(1):4296.

42. Davies NM, Hill WD, Anderson EL, Sanderson E, Deary IJ, Davey Smith G. Multivariable two-sample Mendelian randomization estimates of the effects of intelligence and education on health. Elife. 2019;8.

43. Sargan JD. The Estimation of Economic Relationships using Instrumental Variables. Econometrica. 1958;26(3):393-415.

44. Urda JL, Larouere B, Verba SD, Lynn JS. Comparison of subjective and objective measures of office workers' sedentary time. Prev Med Rep. 2017;8:163-8.

45. Clark BK, Healy GN, Winkler EA, Gardiner PA, Sugiyama T, Dunstan DW, Matthews CE, Owen N. Relationship of television time with accelerometer-derived sedentary time: NHANES. Med Sci Sports Exerc. 2011;43(5):822-8.

Figure 1: Associations of leisure time television watching and computer use with breast and colorectal cancer after adjusting for the four secondary traits. The black dot corresponds to the 1-SD odds ratio and the corresponding error bar to the 95% confidence interval. Abbreviations: BMI: Body mass index; IVW: inverse variance weighting; SD: standard deviation

Figure 2: Bidirectional associations of leisure time television watching and computer use with the four secondary traits: BMI, years of education, smoking, and alcohol. The solid lines correspond to the effects of time television watching and computer use on the four secondary traits while the dashed lines correspond to the effects of the four secondary traits on time television watching and computer use. The black colour corresponds to statistically significant associations and the grey colour to non-significant. All the results, odds ratios and 95% confidence intervals, correspond to a 1-SD change in the levels of the variables. Abbreviations: BMI: Body mass index

<u>able1: Mendelian Randomi</u> Methods			re television w			Leisur	e computer u	se
	Estimates (OR)*	95% CI	P-value	P-value for pleiotropy [†] or heterogeneity [‡]	Estimates (OR)*	95% CI	P-value	P-value for pleiotropy [†] or heterogeneity [‡]
reast cancer								
iverse-variance weighted	1.15	1.05, 1.26	0.002	1×10^{-17}	1.01	0.84, 1.23	0.89	1×10 ⁻⁹
1R-Egger	1.48	0.98, 2.23	0.06	0.22	0.69	0.19, 2.48	0.57	0.55
Veighted median	1.16	1.05, 1.27	0.003		1.06	0.87, 1.28	0.57	
IR-PRESSO	1.12	1.03, 1.20	0.008	3×10 ⁻⁸	1.04	0.88, 1.23	0.62	8×10^{-4}
uminal A breast cancer								
iverse-variance weighted	1.20	1.06, 1.35	0.002	6×10 ⁻¹⁹	1.06	0.84, 1.34	0.62	4×10 ⁻⁶
1R-Egger	1.55	0.90, 2.69	0.11	0.34	1.58	0.35, 7.10	0.55	0.60
Veighted median	1.15	1.01, 1.31	0.03		1.06	0.83, 1.35	0.66	
1R-PRESSO	1.14	1.03, 1.26	0.01	3×10 ⁻⁷	1.06	0.87, 1.31	0.54	0.003
uminal B breast cancer								
iverse-variance weighted	1.14	0.94, 1.38	0.19	0.03	0.89	0.58, 1.36	0.58	0.02
1R-Egger	1.16	0.47, 2.89	0.74	0.96	1.95	0.12, 30.3	0.63	0.57
Veighted median	1.13	0.86, 1.48	0.40		0.97	0.57, 1.67	0.92	
1R-PRESSO					0.82	0.57, 1.17	0.28	0.11
uminal B HER2 negative								
reast cancer								
iverse-variance weighted	1.14	0.96, 1.36	0.13	0.004	1.03	0.76, 1.40	0.84	0.19
1R-Egger	1.07	0.48, 2.39	0.86	0.88	0.27	0.04, 2.25	0.23	0.22
Veighted median IR-PRESSO	1.30	1.03, 1.63	0.03		1.15	0.76, 1.75	0.52	
IER2 enriched breast								
ancer								
verse-variance weighted	1.21	0.91, 1.60	0.19	0.02	0.67	0.40, 1.13	0.13	0.69
1R-Egger	1.31	0.35, 4.95	0.68	0.90	0.08	0.00, 2.16	0.13	0.20
Veighted median	1.25	0.84, 1.86	0.28		0.65	0.31, 1.35	0.25	
1R-PRESSO								
`riple negative breast								
ancer								
verse-variance weighted	1.16	0.99, 1.35	0.06	0.10	0.68	0.50, 0.93	0.02	0.24
1R-Egger	1.54	0.72, 3.29	0.27	0.45	0.41	0.05, 3.35	0.40	0.63
Veighted median IR-PRESSO	1.31	1.04, 1.67	0.02		0.73	0.47, 1.14	0.16	

bbreviations: CI, confidence intervals; MR: Mendelian Randomization; OR: odds ratio; MR-PRESSO: MR pleiotropy residual sum and outlier test The estimates correspond to a standard deviation increase in duration of sedentary activity

P-value or pleiotropy based on MR-Egger intercept

P-value for heterogeneity based on Q statistic

Methods		atching		Leisure computer use				
	Estimates (OR)*	95% CI	P-value	P-value for pleiotropy [†] or heterogeneity [‡]	Estimates (OR)*	95% CI	P-value	P-value for pleiotropy [†] or heterogeneity [‡]
olorectal cancer								
iverse-variance weighted	1.32	1.16, 1.49	2×10 ⁻⁵	9×10 ⁻⁹	0.90	0.70, 1.13	0.33	0.02
IR-Egger	1.35	0.76, 2.39	0.31	0.94	0.35	0.08, 1.55	0.17	0.21
Veighted median IR-PRESSO	1.40	1.20, 1.63	2×10 ⁻⁵		1.08	0.81, 1.45	0.59	
'olorectal cancer in men								
verse-variance weighted	1.45	1.23, 1.67	5×10-6	3×10 ⁻³	0.79	0.61, 1.04	0.10	0.2
1R-Egger	1.72	0.84, 3.53	0.14	0.63	0.61	0.09, 4.06	0.61	0.79
Veighted median	1.52	1.23, 1.88	9×10 ⁻⁵		0.76	0.51, 1.13	0.17	
1R-PRESSO								
olorectal cancer in women								
verse-variance weighted	1.25	1.06, 1.46	0.007	0.003	1.02	0.74, 1.40	0.89	0.05
IR-Egger	1.02	0.50, 2.08	0.96	0.57	0.31	0.04,2.29	0.25	0.24
Veighted median	1.25	1.01, 1.54	0.04		1.20	0.81, 1.79	0.36	
IR-PRESSO					1.08	0.83, 1.42	0.58	0.27
'olon cancer								
verse-variance weighted	1.36	1.19, 1.57	2×10 ⁻⁵	5×10 ⁻⁵	0.90	0.72, 1.14	0.42	0.06
IR-Egger	1.48	0.78, 2.80	0.24	0.80	0.26	0.05, 1.42	0.12	0.14
Veighted median	1.49	1.25, 1.79	2×10 ⁻⁵		0.96	0.68, 1.34	0.82	
IR-PRESSO								
lectal cancer								
verse-variance weighted	1.60	1.32, 1.93	2×10 ⁻⁶	8×10 ⁻⁷	0.66	0.49, 0.89	0.006	0.57
IR-Egger	1.97	0.82, 4.71	0.13	0.63	0.88	0.13, 6.05	0.90	0.76
Veighted median IR-PRESSO	1.86	1.48, 2.36	3×10 ⁻⁷		0.81	0.53, 1.25	0.34	

bbreviations: CI, confidence intervals; MR: Mendelian Randomization; OR: odds ratio; MR-PRESSO: MR pleiotropy residual sum and outlier test

The estimates correspond to a standard deviation increase in duration of sedentary activity

P-value or pleiotropy based on MR-Egger intercept

P-value for heterogeneity based on Q statistic

Methods		atching	Leisure computer use					
	Estimates (OR)*	95% CI	P-value	P-value for pleiotropy [†] or heterogeneity [‡]	Estimates (OR)*	95% CI	P-value	P-value for pleiotropy [†] or heterogeneity [‡]
rostate cancer								
verse-variance weighted	0.94	0.84, 1.06	0.34	3×10 ⁻¹²	1.08	0.89, 1.34	0.42	0.01
IR-Egger	1.19	0.71, 1.99	0.51	0.37	0.70	0.19, 2.56	0.59	0.5
Veighted median	0.94	0.83, 1.08	0.41		1.13	0.88, 1.46	0.33	
IR-PRESSO	0.92	0.84, 1.02	0.13	1×10 ⁻⁵	1.14	0.96, 1.35	0.13	0.09
dvanced prostate cancer								
verse-variance weighted	0.95	0.81, 1.13	0.59	3×10 ⁻⁴	0.91	0.69, 1.22	0.54	0.1
IR-Egger	1.46	0.68, 3.16	0.33	0.26	1.05	0.14, 8.17	0.96	0.89
Veighted median	0.82	0.66, 1.02	0.07		0.96	0.62, 11.48	0.84	
IR-PRESSO								

'able3: Mendelian Randomization estimates for sedentary behaviour and prostate cancer risk

bbreviations: CI, confidence intervals; MR: Mendelian Randomization; OR: odds ratio; MR-PRESSO: MR pleiotropy residual sum and outlier test

The estimates correspond to a standard deviation increase in duration of sedentary activity

P-value or pleiotropy based on MR-Egger intercept

P-value for heterogeneity based on Q statistic